Abstract
Hepatocellular carcinoma (HCC) is one of the most commonly diagnosed cancers globally, yet its pathogenesis remains incompletely understood. Among the various mechanisms contributing to HCC development, small RNAs, such as microRNAs (miRNAs), play a significant role. miRNAs are non-coding RNAs, typically 20-30 nucleotides long, that regulate gene transcription by binding to RNAs, affecting downstream signaling pathways. One such miRNA, hsa-miR-130b-3p, has been associated with cancer development, including HCC, although the full extent of its involvement remains unclear. This study aimed to explore the link between hsa-miR-130b-3p and HCC using bioinformatics analyses and in vitro assays. Publicly available databases were utilized for expression profiling, mRNA and lncRNA target prediction, pathway enrichment, and methylation analysis. In vitro experiments were conducted using a hsa-miR-130b-3p inhibitor in HepG2 cells to assess its effects on proliferation, migration, and oxaliplatin sensitivity. Our findings show that hsa-miR-130b-3p is upregulated in multiple cancers, including HCC, targeting cancer-related genes and interacting with various lncRNAs. Inhibition of hsa-miR-130b-3p reduced cancer cell proliferation and migration, while enhancing drug sensitivity to oxaliplatin. These results suggest that hsa-miR-130b-3p may play a role in HCC pathogenesis, but further studies are required to fully understand its mechanisms.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
